Scholarlink

Background <p>Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy. Sentinel lymph node biopsy (SLNB) might be omitted for various reasons, such as comorbidities. This study evaluates the recurrence and survival in MCC for patients with different SLNB status.</p> Methods <p>A retrospective review included patients from 1999 to 2024 with clinical N0, resectable MCC.</p> Results <p>A total of 696 patients were identified (median age 76 years; 68% male). Sentinel lymph node biopsy was performed in 75%, and 35% of patients had a positive SLNB. Reasons for omission of SLNB included comorbidities (34%), patient choice (31%), lack of lymphoscintigraphy drainage (18%), and other/unknown (17%). Patients who omitted SLNB were older (79 vs. 75 years, <i>P</i> &lt; .001) and more likely to experience recurrence (58% vs. 30%, <i>P</i> &lt; .001). Median follow-up was 3 years. Median recurrence-free survival (RFS) (4.2 years vs. 8.8 months, <i>P</i> &lt; .0001), disease-specific survival (DSS) (not reached for either, <i>P</i> &lt; .0001), and overall survival (OS) (6.8 vs. 3.6 years, <i>P</i> &lt; .0001) were longer for patients who underwent SLNB. On multivariable analysis, RFS (HR 2.0, <i>P</i> &lt; .001), DSS (HR 1.7, <i>P</i> = .01), and OS (HR 1.3, <i>P</i> = .04) remained longer for patients who underwent SLNB.</p> Conclusions <p>Patients with MCC who omitted SLNB had significantly worse RFS, DSS, and OS than those who underwent SLNB. This study supports the role of SLNB for MCC&#xa0;whenever feasible, with great&#xa0;utility in staging and a positive trend on recurrence and survival.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node Biopsy

  • 期刊论文

  • 发表日期：

    2025年10月30日

查看全文
  • Michelle M. Dugan,
  • Caitlyn Balsay-Patel,
  • Nicholas Chin,
  • Jacob Israeli,
  • Kimberly R. Ward,
  • Matthew Nichols,
  • Stephanie Greenbaum,
  • Wenyi Fan,
  • C. Wayne Cruse,
  • Michael Harrington,
  • Rogerio I. Neves,
  • Ricardo J. Gonzalez,
  • Matthew C. Perez,
  • Amod A. Sarnaik,
  • Vernon K. Sondak,
  • Jane L. Messina,
  • Ahmad A. Tarhini,
  • Nikhil Khushalani,
  • Andrew S. Brohl,
  • Joseph Markowitz,
  • Zeynep Eroglu,
  • Lilit Karapetyan,
  • Kenneth Y. Tsai,
  • Jonathan S. Zager

摘要

Background

Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy. Sentinel lymph node biopsy (SLNB) might be omitted for various reasons, such as comorbidities. This study evaluates the recurrence and survival in MCC for patients with different SLNB status.

Methods

A retrospective review included patients from 1999 to 2024 with clinical N0, resectable MCC.

Results

A total of 696 patients were identified (median age 76 years; 68% male). Sentinel lymph node biopsy was performed in 75%, and 35% of patients had a positive SLNB. Reasons for omission of SLNB included comorbidities (34%), patient choice (31%), lack of lymphoscintigraphy drainage (18%), and other/unknown (17%). Patients who omitted SLNB were older (79 vs. 75 years, P < .001) and more likely to experience recurrence (58% vs. 30%, P < .001). Median follow-up was 3 years. Median recurrence-free survival (RFS) (4.2 years vs. 8.8 months, P < .0001), disease-specific survival (DSS) (not reached for either, P < .0001), and overall survival (OS) (6.8 vs. 3.6 years, P < .0001) were longer for patients who underwent SLNB. On multivariable analysis, RFS (HR 2.0, P < .001), DSS (HR 1.7, P = .01), and OS (HR 1.3, P = .04) remained longer for patients who underwent SLNB.

Conclusions

Patients with MCC who omitted SLNB had significantly worse RFS, DSS, and OS than those who underwent SLNB. This study supports the role of SLNB for MCC whenever feasible, with great utility in staging and a positive trend on recurrence and survival.